On Wednesday, RBC Capital Markets adjusted its view on Teladoc Health Inc. (NYSE:TDOC), raising the price target on the company's stock to $10.00 from the previous $9.00. The firm has maintained an Outperform rating on the shares.
The adjustment comes ahead of Teladoc's third-quarter 2024 earnings report, estimated to be released on October 23, 2024. RBC Capital's analysis indicates two main areas of interest for the upcoming report: the revenue and trends of BetterHelp, Teladoc's online counseling service, and any strategic changes that may be introduced by the new CEO.
Despite a consecutive quarterly decline in the number of BetterHelp users, RBC Capital notes a slowdown in the rate of this decline during the third quarter. Moreover, a significant uptick in BetterHelp app usage was observed in September, signaling potential improvement as the year progresses.
As for strategic updates from Teladoc's new leadership, the analyst firm does not anticipate substantial information until early 2025. The slight increase in the price target reflects cautious optimism about the potential reversal of recent downward trends in user engagement with BetterHelp.
In other recent news, Teladoc Health Inc. has undergone significant changes. The company announced the resignation of its Chief Operating Officer, Michael Waters (NYSE:WAT), due to modifications in the company's leadership structure. Alongside this, the firm has made key appointments, including Joseph Catapano as its new Senior Vice President and Chief Accounting Officer.
In terms of financial performance, Teladoc surpassed adjusted EBITDA expectations in its second-quarter earnings report. However, the company anticipates potential contraction in its BetterHelp segment, attributed to rising customer acquisition costs.
Various firms have adjusted their views on Teladoc's future performance. Jefferies increased the company's price target while maintaining a Buy rating, and Piper Sandler reduced its price target but retained an Overweight rating. Meanwhile, firms like Deutsche Bank and Citi have maintained a neutral stance due to challenges in the BetterHelp segment.
New CEO, Chuck Divita, is actively addressing these issues, hinting at potential reorganization or divestiture of the behavioral segment. These are among the recent developments for Teladoc as the company navigates its current challenges and growth phase.
InvestingPro Insights
To complement RBC Capital's analysis, recent data from InvestingPro offers additional context on Teladoc Health's financial position. The company's market capitalization stands at $1.49 billion, reflecting its current valuation in the telehealth sector. Despite the challenges noted in the article, Teladoc has shown a strong return over the last month, with a 21.14% price total return as of the latest data.
InvestingPro Tips highlight that Teladoc's valuation implies a strong free cash flow yield, which could be of interest to value-oriented investors. However, it's important to note that analysts do not anticipate the company will be profitable this year, aligning with the article's focus on the company's financial performance and strategic direction.
The upcoming earnings report on October 23, 2024, as mentioned in the article, will be crucial in light of these insights. Investors using InvestingPro can access 5 additional tips to further inform their analysis of Teladoc Health's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.